Neuroendocrine tumours
Research type
Research Study
Full title
Biochemical markers of neuroendocrine tumours.
IRAS ID
221032
Contact name
Martyn Caplin
Contact email
Sponsor organisation
University College London
Duration of Study in the UK
1 years, 9 months, 4 days
Research summary
Neuroendocrine tumours (NET) originate from neuroendocrine cells in the body. Most of these tumours secrete a chemical called serotonin, which is broken down in the body to 5-hydroxyindole acetic acid (5-HIAA). Diagnosis of NET commonly involves the measurement of 5-HIAA in 24 hour urinary collection. However, 24 hour urine collection can be stressful for patients and done inaccurately. A more practical alternative will be to have the measurement done in a blood test. \nMedical treatment of NET involves the use of somatostatin analogues commonly given as injections. A recognised side effect is diarrhoea, and fatty stools which are difficult to flush. The fatty stool is a result of fat malabsorption in the bowel. This in turn can affect the absorption of certain vitamins and minerals. A previous study has reported deficiencies of fat soluble vitamins in patients on this treatment long-term. It will be important to know whether we should consider giving fat soluble vitamin supplements to patients receiving this treatment.\n\nThe aim of this study is to set up a blood test for measuring 5-HIAA and to compare it with the existing urine method. We will also assess the prevalence of symptoms such as diarrhoea and nutritional deficiencies in patients with NET.\n
REC name
South West - Frenchay Research Ethics Committee
REC reference
17/SW/0131
Date of REC Opinion
21 Jul 2017
REC opinion
Further Information Favourable Opinion